ABSTRACT
OBJECTIVE: To investigate pharmacokinetics of dexmedetomidine hydrochloride injection in 36 healthy Chinese volunteers.
ABSTRACT
<p><b>AIM</b>To establish an HPLC-fluorescence method for determination of loratadine in human plasma and evaluate its relative bioavailability.</p><p><b>METHODS</b>An Alltech-C18 column and a mobile phase of acetonitrile-water-glacial acetic acid-triethylamine (90:100:6:0.15) were used. The fluorescence detector was set at Ex 274 nm, Em 450 nm. The flow rate was 1 mL.min-1.</p><p><b>RESULTS</b>The calibration curve was linear over a concentration range of 0.2-30 micrograms.L-1. The limit of quantification was 0.2 microgram.L-1. The average method recoveries varied from 96% to 98%. The results showed AUC, Tmax, Cmax and T1/2 beta between the testing tablets, testing capsules and reference tablets had no significant difference (P > 0.05). Relative bioavailabilities were 107% +/- 17% and 100% +/- 14% respectively.</p><p><b>CONCLUSION</b>The three formulations were bioequivalent.</p>
Subject(s)
Humans , Male , Area Under Curve , Biological Availability , Chromatography, High Pressure Liquid , Methods , Fluorescence , Histamine H1 Antagonists, Non-Sedating , Blood , Pharmacokinetics , Loratadine , Blood , PharmacokineticsABSTRACT
Aim To study relative bioavailablity of cefaclor effervescent tablets in healthy volunteers. Methods According to the crossover design, A volunteers were each orally given a single does of the 0.75 g cefaclor effervescent tablets and cefaclor capsules with an interval of 5 days between the two formulations.The plasma concentrations of the drug were determined by RP-HPLC.Pharmacokinetic parameters were obtained by ATPK programe,and calculated on the basis of open single compartment model.Results After a single oral dose, the peak levels in plasma averaged Cmax(31.27?5.81)?g?ml-1 and(30.56?5.25) ?g?ml-1 at (0.58?0.12)h and(0.73?0.17)h and AUC0～4(35.48?4.65) ?g?h?ml-1 and (35.89?2.90) ?g?h?ml-1 for tablet and capsule,respectively. Conclusion The result shows that two formulations are bioequivalence.